Scholarlink

<p>Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality, with resistance to PD-1 immune checkpoint inhibitors presenting a significant clinical challenge. Although the protein tyrosine phosphatase SHP2 has been implicated in immune evasion, its precise role in NSCLC and contribution to anti-PD-1 resistance remain poorly understood. To address this, we conducted a CRISPR-based screen which identified SHP2 as a pivotal factor promoting tumor escape from CD8 + T cell-mediated killing. SHP2 expression in NSCLC tissues was analyzed through immunohistochemistry (IHC), qRT-PCR, and Western blotting. Functional assays, including CCK-8 and colony formation, were employed to assess SHP2’s role in tumor proliferation under IFN-γ stimulation. Co-culture experiments with CD8 + T cells evaluated the modulation of immune responses. Mechanistic investigations focusing on IFN-γ/STAT1/IRF1 signaling and CCL5 secretion were analyzed using bulk RNA sequencing, Western blotting, qRT-PCR, ELISA, and proximity ligation assays. We found that SHP2 overexpression correlated with advanced disease and poor prognosis. Mechanistically, SHP2 suppressed IFN-γ/STAT1/IRF1 signaling, reducing CCL5 secretion and impairing CD8 + T cell cytotoxicity. SHP2 knockdown restored immune responses and sensitized tumors to anti-PD-1 therapy. Additionally, pharmacological inhibition of SHP2 with JAB-3312 reversed this immunosuppressive phenotype in NSCLC cell lines and patient-derived organoids (PDOs). Furthermore, in a syngeneic mouse model, JAB-3312 acted synergistically with anti-PD-1 antibodies to suppress tumor growth, an effect driven by a potent T-cell-intrinsic mechanism. These findings establish SHP2 as a key mediator of immune evasion and PD-1 resistance in NSCLC, and targeting SHP2 offers a promising therapeutic strategy to overcome immune resistance and improve responses to checkpoint blockade therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting SHP2 to reverse immune evasion and resistance to anti-PD-1 therapy in non-small cell lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月6日

查看全文
  • Shiwei Chen,
  • Dingguo Wang,
  • Dian Xiong,
  • Lingxian Zhang,
  • Kunchao Li,
  • Jing Wang,
  • Xiong Ma,
  • Xingchen Hu,
  • Lei Zeng,
  • Jianjun Xu,
  • Yongbing Wu

摘要

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality, with resistance to PD-1 immune checkpoint inhibitors presenting a significant clinical challenge. Although the protein tyrosine phosphatase SHP2 has been implicated in immune evasion, its precise role in NSCLC and contribution to anti-PD-1 resistance remain poorly understood. To address this, we conducted a CRISPR-based screen which identified SHP2 as a pivotal factor promoting tumor escape from CD8 + T cell-mediated killing. SHP2 expression in NSCLC tissues was analyzed through immunohistochemistry (IHC), qRT-PCR, and Western blotting. Functional assays, including CCK-8 and colony formation, were employed to assess SHP2’s role in tumor proliferation under IFN-γ stimulation. Co-culture experiments with CD8 + T cells evaluated the modulation of immune responses. Mechanistic investigations focusing on IFN-γ/STAT1/IRF1 signaling and CCL5 secretion were analyzed using bulk RNA sequencing, Western blotting, qRT-PCR, ELISA, and proximity ligation assays. We found that SHP2 overexpression correlated with advanced disease and poor prognosis. Mechanistically, SHP2 suppressed IFN-γ/STAT1/IRF1 signaling, reducing CCL5 secretion and impairing CD8 + T cell cytotoxicity. SHP2 knockdown restored immune responses and sensitized tumors to anti-PD-1 therapy. Additionally, pharmacological inhibition of SHP2 with JAB-3312 reversed this immunosuppressive phenotype in NSCLC cell lines and patient-derived organoids (PDOs). Furthermore, in a syngeneic mouse model, JAB-3312 acted synergistically with anti-PD-1 antibodies to suppress tumor growth, an effect driven by a potent T-cell-intrinsic mechanism. These findings establish SHP2 as a key mediator of immune evasion and PD-1 resistance in NSCLC, and targeting SHP2 offers a promising therapeutic strategy to overcome immune resistance and improve responses to checkpoint blockade therapy.